This episode features two guests who were trailblazers in the development of a landmark cancer drug. Gleevec (imatinib) was a breakthrough in cancer treatment because it helped establish a new group of drugs called targeted therapies. Join us to hear the experiences of Dr. James Shannon, former global head of pharma development at Novartis who helped bring Gleevec to market, and Mel Mann, an early participant in the Gleevec clinical trial who is now the world’s longest-living Gleevec patient.